Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 5:18:617-627.
doi: 10.2147/VHRM.S371912. eCollection 2022.

Magnitude of Coagulation Abnormalities and Associated Factors Among Patients with Heart Diseases at the University of Gondar Comprehensive Specialized Hospital

Melak Aynalem  1 , Tiruneh Adane  1 , Solomon Getawa  1
Affiliations

Magnitude of Coagulation Abnormalities and Associated Factors Among Patients with Heart Diseases at the University of Gondar Comprehensive Specialized Hospital

Melak Aynalem et al. Vasc Health Risk Manag. .

Abstract

Background: Heart disease is a leading cause of hospitalization, death, and poor physical function due to comorbid conditions such as atrial fibrillation and stroke. It affects the blood hemostatic system, vasculature, and flow dynamics, causing both arterial and venous thrombosis. Thus, this study aimed to determine the magnitude of coagulation abnormalities among patients with heart disease attending the University of Gondar Comprehensive Specialized hospital.

Methods: A cross-sectional study was conducted on a total of 98 patients with heart disease. Pretested structured questionnaires were used to collect data on socio-demographic and clinical variables. About 6 mL of venous blood was collected with the vacutainer method and analyzed using Huma cue-due plus and Sysmex KX-21N hematology analyzers for assessing coagulation abnormalities. Stool samples were processed via a direct wet mount. Thin and thick blood films were examined to assess malaria parasites. Data was entered into EPI-Info version 3.5.3 and then transported to SPSS version 20 for analysis. Descriptive statistics were summarized using frequency and percentage. Univariate and multivariate logistic regression models were fitted to identify factors associated with coagulopathy. P-value <0.05 was considered to be statistically significant.

Results: The overall magnitude of coagulation abnormalities (thrombocytopenia, prolonged prothrombin time, and activated partial thromboplastin time) in patients with heart diseases was 85.7% (95% CI: 81.96, 89.45). Besides, prolonged prothrombin time, prolonged activated partial thromboplastin time, and thrombocytopenia were detected in 83.7%, 33.7%, and 12.2% of the study participants, respectively. Participants who are taking medications for chronic disease (AOR = 0.17; 95% CI: 0.04, 0.69), participants with stroke (AOR = 20; 95% CI: 14.7, 35), and participants taking antibiotics (AOR = 8.17; 95% CI: 1.66, 40.27) were significantly associated with prolonged coagulation time.

Conclusion: This study showed that patients with heart disease had prolonged prothrombin time, activated partial thromboplastin time, and thrombocytopenia. Therefore, coagulation parameters are required to be checked regularly to monitor coagulation disorders and their complications in heart disease patients.

Keywords: Ethiopia; Gondar; cardiovascular diseases; coagulation abnormalities; heart diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest in relation to this work.

Figures

Figure 1
Figure 1
Magnitude of coagulation abnormalities among patients with heart disease at the University of Gondar comprehensive specialized hospital.
Figure 2
Figure 2
Mixing test algorithm for the determination of factor deficiency and inhibitory among patients with heart disease at the University of Gondar comprehensive specialized hospital.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. World Health Organization: Cardiovascular diseases (CVDs) 2021. Available from: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1. Accessed November 2, 2021.
    1. Colin D, Ties B, Doris M. Global and regional causes of death. Br Med Bul. 2009;92:7–32. - PubMed
    1. Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. Eur J Cardiovascular Nursing. 2002;1(4):273–288. - PubMed
    1. Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol. 2021;1–17. - PMC - PubMed
    1. Shin J, Edelberg JE, Hong MK. Vulnerable atherosclerotic plaque: clinical implications. Curr Vasc Pharmacol. 2003;1(2):183–204. - PubMed